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Abstract
Cardiovascular diseases (CVD) are the foremost cause of death worldwide. The main
risk factor for CVD is uncontrolled hypertension (HTN). The prescription of only
anti-hypertensive regimens in the management of HTN is becoming more challenging
due to the high cost and adverse effects linked to the persistent usage of the drugs.
Eighteen participants completed the study by consuming 2g of Hibiscus sabdariffa or
oolong tea twice daily for six weeks. We lost an additional twelve participants in the
study due to the COVID-19 pandemic. Central arterial stiffness was analyzed as
cfPWV using applanation tonometry technique. The HS tea intervention (n=11) had a
significant positive effect on SBP (P =0.02), DBP (P =0.001) and HR (P =0.03). Also, the
HS tea consumption led to a non-significant (p=0.44) reduction in cfPWV (-0.5m/
s) when compared to control tea (+0.3m/s). Although, the decease in cfPWV could
be clinically significant, but will need to be verified with larger sample size.

xii

1 Introduction
Recently, there have been drastic changes in the approach used in the treatment of
various diseases, including high blood pressure and other cardiovascular diseases. The
advent of several complementary alternative therapies has been proven to be very effective
in lowering blood pressure, as well as reducing the potential risks of developing
cardiovascular diseases (CVDs) (Whelton et al., 2018). According to the recent trends in
the use of herbal tea as an alternative therapy in the treatment of hypertension (Mittal &
Singh, 2010; Tabassum & Ahmad, 2011), the use of Hibiscus sabdariffa (Hs) tea might
offer a cost-effective alternative to reduce the socio-economic burden associated with the
treatment of hypertension, especially in the poorer states of the US, and in developing and
low-income countries (where insufficient treatment has been a major contributing factor to
the high prevalence of hypertension and other CVDs). The treatment of hypertensive
individuals with only the available conventional anti-hypertensive regimens is becoming
more challenging due to the high cost of the drugs, incomplete adherence to daily intake of
pills, combination therapy to achieve maximum drug effect, and undesirable adverse
effects associated with prolonged usage of different drug regimens (August, 2004; Susalit
et al., 2011; Wang & Xiong, 2012).

1.1 Hypertension
The World Health Organization (WHO, 2013) defined hypertension as a chronic
condition that is characterized by a continual rise in the pressure at which blood flows in
1

the blood vessels, which makes it hard for the heart to pump blood into the circulation.
Diagnosis of hypertension is established when an individual has systolic blood pressure
(SBP) of ≥ 130mmHg and diastolic blood pressure (DBP) of ≥80mmHg, this is in
accordance with the guidelines formulated by the American Heart Association (AHA).
(Whelton et al., 2018). High blood pressure is one of the leading risk factors that contribute
to a high prevalence of cardiovascular diseases (CVDs) worldwide. Cardiovascular
diseases encompass several groups of other heart diseases such as ischemic heart disease
(IHD), coronary artery disease (CAD), congestive heart failure, cerebrovascular disease,
and myocardial infarction (MI) (Mendis et al., 2011). Uncontrolled high blood pressure
has also been attributed to be the leading cause of chronic renal failure in most of the
countries with a high prevalence of hypertension (Pierdomenico et al., 2009).
Implementing lifestyle changes, such as dietary intervention with conventional therapy,
can help delay or mitigates increases in blood pressure, thereby decreasing the risk of
developing CVD and organ damage associated with poorly controlled high blood pressure.
1.1.1 Causes of hypertension
Hypertension (HTN) can be classified as either; primary/essential or secondary
HTN based on the causative factors. Currently, about 90-95% of cases of hypertension in
adults are primary HTN, while only 5% of cases are classified as secondary HTN. Primary
or essential type HTN is usually of unknown etiology and can sometimes be referred to as
idiopathic. However, several associated risk factors have been implicated in the
development of HTN, and these factors have been broadly categorized as either genetic or
2

environmental factors. Genetic alterations: overexpression or underexpression of specific
genes have been reported as an unchangeable factor associated with HTN. High blood
pressure can be inherited and run in families, with an incidence of heritability of about 1530% for DBP and 15-40% for SBP ((Padmanabhan, Aman, & Dominiczak, 2019).
Similarly, certain genetic disorders such as Liddle’s syndrome (autosomal dominant
mutation in sodium channel), a mutation in the gene that results in excess production of
cortisol, glucocorticoid-remediable aldosteronism (GRA) have been identified in the
development of genetic HTN (Levanovich, Diaczok, & Rossi, 2019).
Environmental factors linked to HTN include aging, obesity, high consumption of
alcohol, excess dietary salt intake, stressful lifestyle, potassium deficiency sedentary
lifestyle, chronic intake of caffeine and other sympathomimetic agents (i.e., exciting the
sympathetic nervous system) which are all classified as hypertensinogenic factors. An
increase in body weight, specifically excess fat in the abdomen is one of the most common
hypertensinogenic factors. Several studies have reported a positive correlation between
weight gain and increased BP while controlling body weight in healthy individuals can
significantly reduce both SBP and DBP (Rafiee, Khaledi, Madmoli, Zafari, & Lotfizadeh,
2019). Obesity has been reportedly linked to type II diabetes mellitus (insulin resistance),
hyperlipidemia, deposition of fat droplets in the arterial wall (atherosclerosis), and left
ventricular hypertrophy; which can all result in the development of HTN and other CVDs.
Although, the mechanism of obesity-induced HTN has not been clearly proven; however,
an increase in plasma volume in overweight individuals can subsequently increase cardiac
3

output and BP. Similarly, possible vasoconstriction in obese individuals and enhanced
renin release from the kidney can both increase sympathetic nerve activity (Tesauro &
Cardillo, 2011).
Secondary HTN, which accounts for only about 5-10% cases of global HTN, occurs
due to an underlying medical condition that is usually reversible once the triggering
medical condition is treated promptly. The diagnosis and onset of secondary HTN vary by
age and clinical symptoms; however, secondary HTN has been reported to be more
prevalent among younger adults within the age of 18-40 years (Charles, Triscott, & Dobbs,
2017). The associated causes of secondary HTN usually vary between adults and
preadolescent children; although, medical conditions such as kidney disease, renovascular
disease, hyperlipidemia, diabetes mellitus, pheochromocytoma (tumor producing excess
catecholamines), obstructive sleep apnea, and pregnancy are linked to secondary HTN
across all adult ages. Other uncommon etiology of secondary HTN includes medications
such as oral contraceptives, non-steroidal anti-inflammatory drugs (NSAIDs), hormonal
therapy, several chemotherapeutic drugs, and some recreational drugs (Grossman &
Messerli, 2012).
1.1.2 Prevalence of hypertension
The recent redefinition of HTN in 2017 and 2018 by ACC/AHA and European
Society of Hypertension (ESH), respectively, from 140/80mmHg to 130/80 mmHg, which
was formerly classified as prehypertensive, has greatly increased the prevalence of HTN
4

in the US and other countries in the world. The current global prevalence of HTN among
young (>45 years) and older adults before the reclassification by AHA/ESH is about 3035%; however, while applying the updated definition of HTN, the global prevalence in
adults is now > 60% (Touyz, 2019). The current guideline suggested prompt and intense
implementation of treatment to lower the blood pressure, especially SBP below 140
mmHg, and this has been associated with a significant reduction in mortality rate from
stroke and other CVDs (Salam et al., 2019).
The influence of geographical regions classified as developed or developing
countries on the global prevalence of HTN cannot be underestimated, although factors such
as genetics and environmental factors have a significant influence on the geographical
distribution of HTN. According to a recent report of the world health organization (WHO,
2013), prevalence rate of HTN is high (about 46%) in Africa and other developing
countries, while low prevalence rate of (35%) was reported by WHO in America region
(Al Kibria, 2019). Ethnicity or race has also been reportedly shown to influence the global
prevalence of HTN. The high incidence rate of HTN among Latinos, Asians, and African
Americans living in the US has been reported when compared with Caucasians. The high
blood pressure among non-Caucasians might be related to several factors such as
socioeconomic status, high dietary salt intake, heredity, and low level of renin-angiotensin
has been detected in the plasma of African American.
Gender and age have been reportedly shown to affect the awareness and
management of HTN especially among the young adults within the age of 18 to 54 years
5

when compared with older adults of age >55 years, thus influencing the global prevalence
of HTN (Tadic, Cuspidi, Grassi, & Ivanovic, 2019). The pathophysiology differences
associated with gender are related to variation in sex hormones, components of the reninangiotensin-aldosterone system (RAAS), and the sympathetic nervous and nitric oxide
systems (EUGenMed et al., 2016). The cardioprotective effect of estrogen, most notably
in premenopausal women, can be related to the low incidence of HTN and reduce the risk
of developing CVDs when compared with men within the same age range. Estrogen plays
a vital role in the activation of nitric oxide (NO), which is a potent vasodilator, inhibits the
activation sympathetic nervous system and decreasing the activity of RAAS by blunting
the production of angiotensin-converting enzyme (ACE) which blocks the formation of
angiotensin II (Ang II). Blocking Ang II, which is a potent vasoconstrictor, is highly
essential in the regulation of blood pressure. However, male sex hormone androgens can
increase the synthesis of angiotensinogen II from the liver cells, which subsequently result
in increased production of Ang II. Similarly, androgens can also enhance the reabsorption
of sodium ion from the proximal convoluted tubules of the kidney via the androgen
receptors, resulting in increased vasoconstriction and high blood pressure(Song, Ma,
Wang, Chen, & Zhong, 2019).
Several contributing factors, such as the high incidence of smoking and
hyperlipidemia, which are more prevalent in men, can account for gender differences in
the prevalence of hypertension. Variations in the pharmacokinetics and pharmacodynamics
response to antihypertensive drugs between men and women could also account for gender
6

differences in the prevalence of HTN. Women are more likely to develop adverse drug
effects than men, alteration in drug metabolism by female sex hormones could reduce the
clinical response of women to antihypertensives (Ueno & Sato, 2012).
1.1.3

Treatment of Hypertension
According to the recent guidelines in the diagnosis and treatment of HTN by

ACC/AHA, recommendations for treatment have been revised based on the new directions
that redefined HTN as SBP ≥ 130mmHg and DBP ≥ 80mmHg. However, not all individuals
who are classified as being hypertensive based on recent ACC/AHA definition are
recommended to commence treatment with antihypertensive drugs. Eligibility for
antihypertensive recommendation is based on age (>65 years) and the presence of
preexisting clinical medical conditions, such as diabetes mellitus, chronic renal disease,
atherosclerosis, and other CVDs. At the same time, dietary/lifestyle modifications are
recommended to hypertensive patients who do not meet the eligibility criteria (Khera et al.,
2018).
Several antihypertensive therapies, ranging from ACE inhibitors, calcium channel
blockers, beta-blockers, α-blockers, vasodilators, and diuretics have helped to normalize
blood pressure in individuals with high blood pressure. However, despite the availability
of different types of antihypertensive drugs, only about 36 million hypertensive individuals
out of 1.4 billion of affected people globally, had their blood pressure controlled (Control
& Prevention, 2012). Studies have shown that about 40-60% of individuals with
7

uncontrolled BP were due to incomplete adherence or non-compliance to drugs, while
others were due to lack of awareness (Control & Prevention, 2012). High prevalence of
uncontrolled BP among hypertensive individuals has contributed to increased risk of
developing cardiovascular disease, most notably in the developing countries where socioeconomic burden has affected the affordability of high costs of antihypertensive drugs.
Similarly, adverse effects associated with prolonged use of a single drug type, or
combination regimen, have been a great challenge in the management of HTN. Recently,
the use of specific antihypertensive drugs has been linked with the development of cancer,
although many of the links are still controversial. For instance, treatment with some
calcium-calcium channel blockers has been associated with the incidence of breast cancer
(Wright et al., 2017), while the use of common diuretics; hydrochlorothiazide (HCT) and
thiazide have been linked with skin cancers and ovarian cancers respectively (Huang et al.,
2016; Pedersen et al., 2018).

1.2 Pathophysiology of hypertension.
Interaction between several mechanisms that affect the vascular system, arterial
system, sodium and fluid balance in the body are all implicated in the pathogenesis of HTN.
The role of an arterial system comprising of the aorta (largest arteries), small arteries, and
the microcirculation (arterioles and capillaries) in the development of HTN cannot be
underestimated. Small arteries and arterioles with a diameter (<300µm) are highly resistant
vessels that play a significant role in the regulation of BP. According to Poiseuille’s law,
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out of the three major factors that determine the resistance to blood flow in the vessels, the
diameter of vessels is the essential factor. The primary mechanisms that are involved in the
pathogenesis of HTN are discussed below.
1.2.1 Autonomic nervous system
Alteration in the autonomic nervous system, which consists of both the sympathetic
nervous system (SNS) and parasympathetic nervous system (PNS), plays a crucial role in
the regulation of BP. Stimulation of either SNS or PNS, which depends on the type of
receptors (α or β) that binds the neurotransmitters (either catecholamines or acetylcholine),
can cause alteration in heart rate and blood vessel tone. Activation of SNS is usually
excitatory, causing both increases in heart rate and vasoconstriction, which are essential
factors that precipitate an increase in BP, while PNS has an inhibitory effect on heart rate.
Activation of sympathetic nervous activity to the heart, skeletal muscles, blood
vessels, and kidney contributes to a rapid increase in BP and may lead to subsequent
development of HTN, cardiac arrhythmias, atherosclerosis, left ventricular hypertrophy
and other CVDs. The SNS is activated by several factors such as obstructive sleep apnea
(OSA), genetics (about 50% of SNS over-reactivity can be inherited), stress, increase
dietary calorie intake, obesity, chronic exposure to caffeine, and some other
sympathomimetic agents (Grassi & Ram, 2016). Similarly, degrees of fat distribution in
the body and general obesity has been associated with enhanced SNS activity.
Microneurography analysis has confirmed the evidence of epinephrine spillover in the
9

plasma with the high concentration deposited in the kidney, thus justifying the correlation
between the obesity, SNA activation, and HTN (Seravalle & Grassi, 2017).
1.2.2 Alteration in Vascular smooth muscle cell
All the blood vessels composed of vascular smooth muscle cells (VSMC), except
for the capillaries. The VSMCs are located in the middle part (tunica media) in the structure
of the blood vessel. The layers of VSMC are usually thicker in arteries when compared to
the veins due to the pressure of blood flowing through the venous bed. The VSMC cells
are differentiated and formed from the neural crest cells of main aorta and arteries;
however, alterations in the synthesis of the VSMC, such as immature proliferation, growth,
and migration have been implicated in the pathogenesis of HTN (Fisher, 2010; Kietadisorn,
Juni, & Moens, 2012). The proliferation of VSMCs, which can either be an abnormal
increase in the size of the cells (hypertrophy) or increase in the number of cells
(hyperplasia), or presence of both pathological changes have been linked to abnormal
growth in VSMC (Marx, Totary-Jain, & Marks, 2011).
Several stimulating growth factors, which are called mitogens, such as endothelin,
thrombin, interleukin-1, platelet-derived growth factor (PDGF), vasopressin, serotonin,
bradykinin, and angiotensin II are responsible for contraction of VSMC (Bacakova et al.,
2018). The constriction of VSMCs, mediated by the contractile agonists listed above,
contributes significantly to a decrease in the diameter of blood vessels. Considering
Poiseuille’s law, three factors, which are vessel diameter, vessel length, and blood
10

viscosity, determines the resistance to blood flow in the vessel. Decreases in diameter
contribute majorly to increased peripheral resistance in blood vessels and subsequent
increase in arterial blood pressure.
1.2.3 Endothelial dysfunction
The endothelial cells, which is a semi-permeable layer (located in the luminal parts
of the blood vessel), often referred to as “tunica intima or tunica interna,” form direct
contact with blood. Mechanical or biochemical damage to endothelial cells contributes to
endothelial dysfunction and the pathogenesis of HTN. Increased production of harmful
substances, such as free radicals (superoxide anions, hydroxyl ions, and other oxidants), in
the blood and their attachment to the endothelium constitutes biochemical damage to the
endothelium (Drummond, Selemidis, Griendling, & Sobey, 2011; Zeng, Villar, Yu, Zhou,
& Jose, 2009). Damaged endothelium stimulates the activation of inflammatory cascades
that leads to the production of certain substances such as platelet-derived growth factor
(PDGF), nuclear factor kappa B (NF-kB), tumor necrosis factor (TNF), vascular cell
adhesion molecules (VCAM), interleukins and other inflammatory cells that stimulate
proliferation of VSMC, vasoconstriction and eventually HTN (Masi, Uliana, & Virdis,
2019). Endothelial cells also produce substances that mediate the dilation of blood vessels
and vascular tone. Nitric oxide (NO), endothelial-derived hyperpolarizing factors, and
prostacyclin are potent vasodilators, and decreased production or release of vasodilators
from the endothelial cells can also cause endothelial dysfunction and thus contribute to the
development of HTN (Daiber et al., 2019).
11

1.2.4 Renin-angiotensin-aldosterone system (RAAS).
The RAAS system, which is considered both an endocrine and paracrine system,
entails a series of hormonal cascades that exert its effect on renal function, maintenance of
sodium/water balance, and physiological regulation of blood pressure. Pathological
activation of RAAS in certain disease conditions plays a vital role in the pathogenesis of
HTN. The release of renin initiates the activation of RAAS, a glycoprotein secreted and
stored in the juxtaglomerular cells (JG) of the nephron. It has been reported that JG cells
also contain β1 adrenergic receptors, which can be stimulated by the sympathetic nervous
system, thus inducing the release of renin from the JG cells. Signaling from macula densa
cells due to deficiency of sodium ions and water imbalance can also stimulate the release
of renin. Renin acts on its substrate called angiotensinogen, which is secreted mainly in the
liver, converting it into an inactive peptide named angiotensin I (Ang I). Hydrolysis of Ang
I by angiotensin-converting enzyme (ACE) forms angiotensin II (Ang II), which is a potent
vasoconstrictor that mediates increased BP and organ damage associated with uncontrolled
HTN (Mannelli, Rossi, Vanderriele, & Parenti, 2018).
The Ang II acts by binding to its specific receptors to mediate its effect, two different
types of receptors, angiotensin type I (AT1) and type II (AT2), have been identified. The
binding of Ang II to the AT1 receptor mediates most of the effects of Ang II. Also, apart
from the vasoconstriction effect of Ang II, it stimulates the release of aldosterone from the
adrenal cortex. Aldosterone plays a crucial role in maintaining normal homeostasis by
controlling sodium, potassium, and water balance in the body. Increased production of
12

aldosterone enhances the reabsorption and retention of sodium and water in the body, thus
causing an increase in blood volume, blood pressure, and development of HTN
(Provenzano & Sparks, 2019).

1.3 Arterial stiffness
1.3.1 The physiological role of Arteries
The arterial system, especially the large arteries, perform a conduit function. The
arteries in a healthy young adult individual deliver adequate oxygenated blood from the
left ventricle of the heart to the systemic circulation. The conduit function of the arteries
ensures the proper supply of blood to the peripheral organs and tissues in the body, and the
efficiency of the conduit function depends on the distensibility and stretching ability of the
large artery (aorta) to accommodate an increase in blood flow. This physiological
stretching ability of the arteries when there is an increase in blood flow widens the diameter
of arteries, decreases peripheral resistance, and thus controls mean arterial blood pressure
(London & Guerin, 1999).
Similarly, another interrelated function of the arteries is the ‘dampen function or
cushion function’(Sun, 2015). During systole, only about 40% of the blood pumped out of
the left ventricle is supplied to the organs and tissues. In contrast, the remaining blood is
stored in the elastic arteries. The aorta recoils during diastole, squeezing the preserved
blood into the peripheral tissues, thus ensuring continuous organ and tissue perfusion. This
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recoil during diastole is also essential to perfuse cardiac muscle with oxygen-rich blood
(W. W. Nichols et al., 2008).
1.3.2 Pathophysiology of Arterial stiffness
The Stiffening of the arteries termed “arteriosclerosis” occurs because of the
alteration in the structure of the arterial wall. The arterial wall consists of smooth muscle
cells, connective tissues (mainly elastin and collagen fibers), and fibrous tissue. The
arrangement of elastin and collagen fibers varies according to the size of the arteries; the
ratio of elastin to collagen is usually high in the aorta/large arteries when compared to
peripheral arteries and arterioles (Wagenseil & Mecham, 2012). The Degenerative changes
observed in the ECM of the tunica media part of the arteries, which is characterized by a
reduction in the elastin/collagen ratio or viscoelastic properties of the artery is the primary
pathophysiology that reflects arterial stiffness (London, Marchais, Guerin, & Pannier,
2004).
Contraction of the left ventricle during systole generates a wave called a pulse
wave, which is palpable at the wrist or at the carotid artery of the neck (and along many
other arteries that are near the skin’s surface). This wave produced during ventricular
ejection is termed an incident wave, and the speed at which the waves travel away from
the heart is called pulse wave velocity. The incident wave can be reflected at any point
during the cardiac cycle, and the timing for the reflected waves depends significantly on
the viscoelastic properties of the arteries (W. Nichols, 1998). Arterial stiffness can cause a
14

significant increase in the pulse wave velocity and untimely return of reflected wave during
systole instead of diastole. In a healthy artery, the reflected wave should return to the heart
during diastole to ensure a continuous supply of blood to coronary arteries, while the early
return of the reflection wave during the systolic phase can augment the incident wave
causing an increase in both pulse pressure and systolic blood pressure.

Figure 1.1

illustrates the incident and refection waves, as well as hemodynamic changes in both
normal and stiffened arteries.

Figure 1.1. (A) Aortic pressure waveform showing both forward traveling wave (incident
wave) and reflected wave of an individual with a normal artery. (B) Aortic pressure
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waveform in an individual with a stiffen artery where the summation of the incident wave
and reflected wave had augmented the pulse pressure (Van Varik et al., 2012).

1.3.2.1 Arterial Stiffness and Hypertension
Arterial stiffness is commonly one of the first contributing mechanisms to the
development of essential hypertension. Disruption in elastin, which is the major ECM
component in the arterial wall, contributes mainly to arterial stiffness and HTN. The large
arteries and aorta serve as capacitance vessels that distend and recoil during systole and
diastole, respectively. However, a stiffened artery requires more pressure to stretch the
arterial wall to pump blood to distal vessels and systemic circulation. The early return of
reflected waves back to the aorta during the systolic phase increases the systolic pressure,
especially in older individuals. In young individuals, PWV is relatively slow due to the late
return of reflected wave at the diastolic phase of the cardiac cycle, thereby increasing the
diastolic pressure.
The importance of altered elastin in the development of arterial stiffness and HTN
was confirmed by an animal model study where elastin was genetically knocked down in
mice. Increased left ventricular pressure, and systolic pressure was observed in modified
mice when compared with wild type mice (Wagenseil & Mecham, 2012). Arterial stiffness
was also significantly increased in elastin-knocked out mice, and this preceded the
observed blood pressure increase. Thus, early detection of increased PWV even before the
development of high blood pressure can be a new clinical marker in the diagnosis of HTN
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and CVDs. While developing a new therapeutic approach targeting the reduction of PWV
and arterial stiffness can significantly reduce the high prevalence rate of HTN and CVDs.
1.3.3 Measurements of Arterial Stiffness
Evaluation of arterial blood pressure and pulse pressure at the brachial artery has
been used as a predictor for the diagnosis of HTN and other cardiovascular diseases.
Although brachial arterial blood pressure does not usually provide accurate analysis of the
pressure in the aorta and large elastic arteries; thus measurements at the brachial artery are
an indirect evaluation of arterial stiffness (Wagenseil & Mecham, 2012). In healthy
individuals with normal arterial distensibility, their aortic blood pressure is usually lower
than the systolic brachial pressure, because the aorta has higher distensibility than other
large arteries. However, in certain circumstances, the brachial arterial blood pressure might
be of the same value as the aortic blood pressure, thus providing an inconclusive marker
of cardiovascular events. The rough and inaccurate measurement of arterial stiffness with
the brachial artery has led to the discovery of several non-invasive methods, such as
Doppler ultrasound, pressure transducer, photoplethysmography and magnetic resonance
imaging (MRI), which can provide a more specific indication of arterial stiffness (Urbina
et al., 2009).
In-vivo measurement of arterial stiffness humans depends on the ratio of pressure
changes in the arteries to the alteration in diameter at both diastolic and systolic phase of
the cardiac cycle. Measuring aortic PWV by recording the pulse wave in the common
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carotid arterial and femoral artery (cfPWV) has been reported as the standard method for
in-vivo measurement of arterial stiffness in humans. The distance between the carotid and
femoral arteries can be measured superficially with a measuring tape, while the pulse wave
can be detected using applanation tonometry. The cfPWV is obtained from a distance/per
unit time of the traveling wave between the two locations. Applanation tonometry, which
makes use of computer software to record both the incident and reflected waves, has been
proven to be a reliable diagnostic tool used in estimating arterial stiffness in clinical and
research cardiovascular laboratories (Crilly, Coch, Bruce, Clark, & Williams, 2007).

1.3.3.1 Applanation Tonometry
Evaluating arterial stiffness by applanation tonometry involves two main
techniques: pulse wave analysis (PWA) and pulse wave velocity (PWV). Mohamed first
invented the use of the PWA technique to access arterial stiffness in 1872, where the
pressure waveforms differences between central and peripheral arteries were analyzed
(Mohamed, 1872). However, the current PWA involves the use of a tonometer to record
the pulse waves of a specific artery. Most commonly, the radial artery and the waves are
automatically analyzed by SphygmoCor computer software. This PWA gives an estimate
of aortic blood pressure waveform when calibrated with individual brachial blood pressure,
thus providing the estimates of central SBP, DBP, PP, and MAP. Apart from the aortic
blood pressure, aortic argumentation index (AIx) can also be obtained from the PWA.
Figure 1.2 shows a sample report of PWV measured at the radial artery indicating the aortic
blood pressure and AIx. The AIx means the augmented aortic systolic blood pressure
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caused by the return of reflected waves at the aorta either at the systolic or diastolic phase,
depending on the mechanical structure of the large arteries (Papaioannou et al., 2004).
Also, the AIx has been reportedly linked to an individual’s heart rate, blood ejection time,
and height. Monitoring arterial stiffness using PWA can be used to provide useful
information about cardiovascular events (Townsend et al., 2015).
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Figure 1.2. Sample recordings of PWA of radial artery obtained from SphygmoCor
applanation tonometry showing the aortic blood pressure (SBP, DBP, MAP, and PP) and
the aortic augmentation indices.
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Pulse wave velocity (PWV) involves the evaluation of the speed of pulse wave,
which is automatically calculated based on the distance traveled by the wave from one
point to another per unit time. Unlike the PWA, measurement of PWV by the SphygmoCor
usually corresponds with the electrocardiogram (ECG) reading, specifically the R-wave of
the ECG, which indicates the start of ejection of blood from the ventricles. The carotid and
femoral arteries are the two points commonly used to estimate pulse wave velocity
(cfPWV). Measurement involves placing a measuring tape to measure the superficial
distance from the aorta (located at the suprasternal notch) to the carotid and femoral
arteries, while time delay from the R-wave to the pulse arriving at the given palpated
arterial site is measured by the tonometer placed on the respective arteries. The
SphygmoCor computer software automatically utilizes the measured distance and time to
evaluate the cfPWV (m/s). Figure 1.3 shows the sample report indicating the carotidfemoral pressure pulse waves, ECG, and cfPWV.
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Figure 1.3. Sample recording of cfPWV obtained from the automatic calculation of the
distance from carotid and femoral sites for a delay time of pulse arrival after the respective
R-waves.

1.3.4 Factors Influencing Arterial Stiffness.
The extent of arterial distensibility depends greatly upon the composition of the
blood vessels, most especially aorta and large arteries. Any factors either modifiable or
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non-modifiable that alter the fundamental structure of blood vessels can result in stiffening
of the arteries. The most important structural components include VSMC, collagen, and
elastin. Aging is one of the essential non-modifiable independent risk factors that induce
the development of arterial stiffness and HTN. An increase in age has been associated with
altered ECM proteins in the blood vessel, such as calcification and fragmentation of elastin
(decrease elastin) and accumulation of collagen, thus reducing the viscoelastic properties
of the vessel wall. This structural disruption in ECM protein would reduce the dampening
function of the arteries and increase PWV with a resultant increase in systolic blood
pressure and pulse pressure.
Several reports have shown the relationship between age and arterial stiffness
(Franklin et al., 1997; Mitchell et al., 2004; Wen et al., 2015). The stiffness is usually more
noticeable in the central artery and aorta when compared to muscular or peripheral arteries.
Evidence has shown a strong correlation between age and carotid artery stiffness, while
there was no correlation between femoral artery stiffness and age (W. Nichols, 2005; van
der Heijden-Spek et al., 2000). Aortic and carotid PWV increases with age with an
approximate value of about 0.1m/s every year with an estimate of almost 10% to 15%
increase during ten years (W. Nichols, 2005). In addition to the alteration in viscoelastic
properties of the vascular wall, the presence of metabolic syndrome and inflammation
could also contribute to age-related arterial stiffness and HTN. The presence of diseases
such as type II diabetes, obesity, dyslipidemia, hyperglycemia, and end-stage renal disease
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could promote vascular aging, stiffening of the arteries, and development of HTN (Ferreira,
Schouten, Smulders, Twisk, & Stehouwer, 2012).
Dietary modifications are one of the modifiable factors that can influence arterial
stiffness. Consumption of alcoholic wine can induce a small but significant decrease in BP,
AIx, PP, and PWV measured at the radial artery, while no significant hemodynamic
changes were observed in participants exposed to non-alcoholic wine (Mahmud & Feely,
2002). Similarly, chronic intake of caffeine, either in the form of a tablet or consumed in
coffee can induce have been associated with an acute increase in AIx and SBP when
compared with participants exposed to placebo or decaffeinated coffee (Waring, Goudsmit,
Marwick, Webb, & Maxwell, 2003).

Other dietary modifications, such as high

consumption of fish (Del Brutto, Mera, Peñaherrera, Peñaherrera, & Costa, 2018) and high
intake of antioxidant vitamins most especially, vitamins A, C, D, E and K (Mozos, Stoian,
& Luca, 2017), have been shown to reduce arterial stiffness.
Lifestyle medications is another modifiable factor that influences changes in arterial
stiffness. Regular exercise either, aerobic endurance or resistance exercise, can induce a
significant decrease in aortic PWV and carotid AIx when compared to individuals with a
sedentary lifestyle (Mutter, Cooke, Saleh, Gomez, & Daskalopoulou, 2017). Cigarette
smoking has also been associated with the development of CVDs. Both short- and longterm smoking can induce endothelial dysfunction, thereby increasing arterial stiffness.
Numerous studies have confirmed the effect of long and short-term smoking on arterial
compliance among active smokers; however, in cases of short smoking, most significant
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changes in arterial compliance are usually observed within the first five minutes after acute
smoking (Kim et al., 2005; Xue et al., 2019). Besides, passive smoking involving long
term exposure to environmental air polluted with tobacco smoke has been associated with
carotid arterial stiffness. However, this depends on the dose of exposed pollutant mixtures
(Ljungman et al., 2018).

1.4 Hibiscus sabdariffa. L
Hibiscus sabdariffa. L (Hs) is an annual herb that belongs to family Malvaceae, and
it is widely known in English as a roselle or red sorrel. The HS plant (figure 1.4) is a tropical
shrub that is commonly grown in many tropical regions of the world, especially in South
East Asia, India, America, Central and West Africa (Ngamjarus et al., 2010). Different
parts of the hibiscus plant, leaves, flowers, and calyx are used medicinally for treatment of
various health issues; however, fresh, or dried calyces of the flower are popularly used to
produce hibiscus tea or sour tea. The phytochemical and pharmacological analysis of Hs
reviewed by several studies has shown the presence of bioactive compounds, which are
mainly: polyphenols.
Phytochemical analysis indicates the presence of five essential polyphenols in HS
and other plant extracts: anthocyanins, flavonoids, anthocyanidins, phenolic and organic
acids. Anthocyanins have been identified as the significant polyphenols compound in the
hibiscus plant, and they confer the red pigment to the calyces of the HS flower (GrajedaIglesias et al., 2016). Four types of anthocyanins have been unearthed and are described
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based on differences in the make-up of their chemical structure, these include Delphinidin
(anthocyanidin), Delphinidin-3-sambubioside (hibiscin), Cyanidin -3-sambubioside, and
Cyanidin-3,5-

diglucoside.

Both

delphinidin-3-sambubioside

and

cyanidin-3-

sambubioside are the most effective anthocyanins in HS extract (Yang et al., 2009).

Figure 1.4. Hibiscus sabdariffa L. flower showing the petals, stigma, and stamen.
(Picture was taken at MTU greenhouse; photo credit: John Durocher).
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1.4.1 Hibiscus sabdariffa. L and Blood Pressure.
The beneficial effect of Hibiscus sabdariffa extracts on lowering blood pressure
both in normotensives and hypertensives have been extensively reported in both human
and animal studies. According to Inuwa et al, there was a significant reduction in SDP,
DBP, mass of the left ventricle of the heart when the effects of HS extract on hypertension
was observed on rats for about ten weeks, although they show no effect on heart rate (Inuwa
et al., 2012). In another comprehensive report by Hopkins et al. (Hopkins, Lamm, Funk, &
Ritenbaugh, 2013), HS extract showed an effective reduction in blood pressure in both
hypertensive and normotensive animals. Several clinical randomized human trials where
dried calyxes of HS were brewed as tea, used as a juice, or directly as an extract on different
populations have confirmed the hypotensive effect of HS. A randomized controlled trial
(RCT), where hypertensive patients were exposed to 10g of dried HS extract per day,
reported a substantial reduction in SBP and DBP after four weeks intervention period
(McKay, Chen, Saltzman, & Blumberg, 2009). Similarly, the hypotensive effect of HS was
compared with Lisinopril (a potent antihypertensive drug) in a double-blind controlled
clinical trial. After four weeks intervention period, a similar reduction in BP was observed
among participants exposed to Lisinopril and HS tea, thus confirming the effectiveness of
HS extract as other pharmaceutical antihypertensive therapies (Herrera-Arellano et al.,
2007).
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1.4.2 Antihypertensive mechanisms of Hibiscus sabdariffa. L
The exact mechanism by which HS mediates a reduction in BP in humans is still
unknown. Studies showing the three main antihypertensive mechanisms HS have been
reported and are compared with the mechanisms of action of most of the generally used
antihypertensive drugs. The identified mechanisms of action include; angiotensinconverting enzyme inhibitors (ACE inhibitor), vasodilator, and diuretic properties
(Alarcón-Alonso et al., 2012; Ojeda et al., 2010; Sarr et al., 2009). The anthocyanins,
specifically delphinidin-3-sambubioside and cyanidin-3-sambubioside, are responsible for
most of the mechanisms involved in lowering BP.

1.4.2.1 Diuretic mechanism
The HS can stimulate the release of nitric oxide which is a vasorelaxant from the
endothelial lining of the blood vessels. The nitric oxide (NO) regulates the rate of blood
flow to the kidney and glomerular filtration rate. The role of NO in normal function of the
kidney has been linked with its ability to increase the reabsorption of sodium from the
kidney tubules. The diuretic property of HS was assessed in an animal model and a
randomized clinical trial, where a decrease in plasma concentration of sodium due to
increased urinary excretion was observed in both hypertensive rats and patients with HBP
after four weeks of exposure to HS extracts. (Kvam, Ofstad, & Iversen, 2000). The diuretic
action HS extract is comparable to the most frequently used diuretics such as
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hydrochlorothiazide (HCT) and furosemide used in the treatment of hypertensive
individuals (Alarcón-Alonso et al., 2012).

1.4.2.2 Hibiscus sabdariffa. L as a vasodilator.
The vasodilating effect of HS extract is induced by the presence of a high
concentration of anthocyanin bioactive compounds in the extract compared to other
polyphenols. (Adegunloye et al., 1996) . The existence of anthocyanin in HS extract has
been implicated in the activation of potassium ion (K+) channels, while activation of K+
causes the rapid efflux of K+ into the extracellular compartment and can stimulate
hyperpolarization of the blood vessel membrane. Hyperpolarization of the membrane
inhibits cardiovascular activity which can stimulate a significant reduction in blood
pressure (Sarr et al., 2009).
Similarly, HS has been shown to reduce BP and HR by inhibiting the SNS. It was
investigated by a study in humans where an increased in sympathetic nervous activity and
BP induced by cold pressor test (CPT) was subsequently inhibited after the administration
of HS tablet (Aliyu, Oyeniyi, Mojiminiyi, Isezuo, & Alada, 2014). Another study
confirmed the vasorelaxant effect of HS by its ability to induce the release of endotheliumderived nitric oxide, which is a potent vasodilator and block the influx of calcium ions.
This was confirmed in an animal model, where hypertensive rats were exposed to 0.3mg/ml
of Hs extract daily for six weeks intervention period, and the vasodilating effect was
observed in the aorta of the rats (Ajay, Chai, Mustafa, Gilani, & Mustafa, 2007).
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1.4.2.3 Angiotensin-converting enzyme (ACE) inhibitor
The capability of HS extract to block the action of ACE is another hypotensive
mechanism. The ACE is vital enzyme that facilitates the conversion of angiotensin-I to
angiotensin-II in the RAAS. The anthocyanins in HS extract compete with the ACE
binding site, thus preventing the formation of Ang II, which is a potent vasoconstrictor.
The ability of HS extract to hinder the ACE activity was investigated in a randomized clinical
trial where hypertensive patients (HTN stage 1 and 2) were exposed to either HS extract or
25mg captopril twice daily (ACE inhibitor drug). The decreased in BP observed among
patients exposed to anthocyanin-rich HS extract was similar to the BP reduction rates
reported among patients on captopril (Ojeda et al., 2010).
1.4.3 Toxicity of Hibiscus sabdariffa. L
Despite the promising hypotensive benefit of HS and its outcome in minimizing the risks
of developing cardiovascular diseases, its safety and contradictions among specific
individuals should be clearly stated. Apart from consuming the pure HS extract, there are
lots of commercially prepared herbal tea, where more than half of the total constituents
consist of HS extract. While HS extract is considered to be safe and natural, the ingestion
of HS extract can as well be harmful to individuals who are taken certain medications
such as hydrochlorothiazide ( frequently used diuretics), acetaminophen, diclofenac, and
other high risk groups (gravid ,lactating women and children). Some pre-clinical trials have
reported a very low degree of acute toxicity when a high dose of HS extract is being
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consumed. At the same time, exposure to more than 300mg/kg daily for a prolonged period
of three months can result in significant hepatoxic effects. The lethal dose (LD50) of HS
extract was confirmed in an in-vivo experimental animal model, where Wister albino rats
exposed to high dosage of 300-2000mg/kg Hs extract per day for 3months showed a
significant increase in liver enzymes and plasma creatinine, thus confirming the damaging
effect on the liver (Fakeye, Pal, Bawankule, Yadav, & Khanuja, 2009). Similarly, in
another animal study, rats exposed to a daily dose of 250-1000 mg/kg revealed no organ
damage

(Prommetta,

Phivthong-ngam,

Chaichantipyuth,

Niwattisaiwong,

&

Lawanprasert, 2006). Based on several studies on HS toxicity dosage, it has been
recommended that a maximum dose that is less than 1000mg/kg is considered safe and
would not induce any organ damage in humans.

1.5 Aim of the Study
The study aimed to examine the effect of Hibiscus sabdariffa tea and oolong tea on
blood pressure and arterial stiffness in healthy human subjects after six weeks of the
intervention period. We hypothesized that individuals who are exposed to a daily intake of
HS tea would have a decrease in blood pressure and arterial stiffness after six weeks of the
intervention period when compared to participants exposed to oolong tea.
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1.6 Significance of the Study
In the recent survey by the WHO, cardiovascular disease remains the number one
cause of death in the United States, as well as low- and middle-income countries in the
world.

High blood pressure has been considered as the major contributing factor

responsible for CVDs. Despite the availability of antihypertensive drugs in many countries
in the world today, more than 50% of hypertensive individuals were unable to control their
HBP (Muntner et al., 2018). High costs of drugs, insufficient treatment due to noncompliance, and undesirable side effects resulting from prolonged use of drugs have been
implicated in poor management of hypertensive individuals. With the growing increase in
uncontrolled HTN, the WHO has estimated the global annual death toll resulting from HBP
would reach 23.5 million by the year 2030 if alternative treatment approaches are not being
implemented (Organization, 2015). Thus, there is a need for urgent intervention to avert
the current increasing rate of uncontrolled HBP in hypertensive individuals, hence the
emerging use of Hibiscus sabdariffa and other complementary alternative therapies in the
management of hypertension.
Numerous studies have investigated the effect of HS extract/tea on reducing blood pressure
both in humans and animals, while HS tea has also been reported to reduce arterial stiffness
in animal and tissue models (GWALA, SİBUOR, Olabu, Pulei, & Julius, 2019). However,
the effect of HS tea on arterial stiffness in humans is still unknown, to the best of our
knowledge, this is the first study to investigate the impact of HS tea on arterial stiffness in
healthy humans.
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2. Methods
2.1 Participants Information.
Forty-five healthy volunteers from Michigan Tech and Houghton community
were assessed for eligibility into the study. Out of the 45 participants assessed,
only 30 (17 males, 13 females) met all the inclusion criteria and were recruited into
the study. The inclusion criteria for participation in this study were; men and women
age 18-45 years, not pregnant, resting systolic blood pressure of at least 110 mmHg,
body mass index (BMI) in the range 18.5-35kg/m2, not on any blood pressure
medication, non-smokers and free of any acute or chronic metabolic diseases.
Throughout the study, a total of 18 participants completed the study, while 12
participants were lost to follow up due to the COVID-19 pandemic (Figure 2.1).

2.2 Study design and Procedures
Initially, an orientation session was held at Michigan Tech’s Clinical and
Applied Physiology lab (CAHP) following fasting for 5 hours by abstaining from food,
caffeinated beverages, alcohol, and strenuous exercise. During the orientation,
detailed study procedures and restrictions were explained to the volunteers. Questions
to determine the subject’s eligibility were obtained using questionnaires; height, weight,
and BMI were also measured and recorded. Potential participants were instructed to rest
for 5 minutes before resting seated brachial blood pressure was measured in triplicate
using an automated sphygmomanometer to screen for participants with low blood pressure
(SBP<110mmHg).
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All eligible participants signed informed written consent and information sheet
before being officially enrolled in the study, and this study was approved by the
Michigan Technological University Institutional Review Board (M1889). Eligible
volunteers were scheduled for a full baseline testing session.
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45 volunteers (n= 45)
Screened for eligibility

Excluded (n= 15)
Did not meet criteria.

30 volunteers (n= 30)
Enrolled and randomized

Placed on Oolong tea
(n=15)

Placed on H.sabdariffa
tea (n= 15)
4 participants lost to 6 weeks
follow-up

8 participants lost to 6 weeks
follow-up

11 HS participants
completed the study

7 Oolong participants
completed the study

Figure 2.1. Schematic illustration of study design and participant enrollment.

The study was a randomized controlled clinical trial (RCT), subjects were randomized into
one of two intervention groups: Hibiscus sabdariffa tea and oolong tea (control
group). Before baseline testing, participants were instructed to fast overnight for a
minimum of 12 hours, without food, drinks (alcohol, caffeine, except water), or
exercise. Participants reported to SDC sleep research lab, where each was instructed to
rest for 5 minutes before measuring three seated blood pressures. They were also told to
lay supine for 5 minutes
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before supine blood pressure was assessed in triplicate as well. Average values were
recorded for both seated and supine blood pressures. Subjects in each group were instructed
to consume the tea twice daily (one tea bag in the morning and one in the late
evening/night) for six weeks.
Dried calyces of organic Hibiscus sabdariffa tea and oolong tea leaves were
commercially purchased, and 2g of dried leaves were measured and put in each of the
teabags. Also, commercially bagged Hibiscus sabdariffa and oolong Alvita brand teabags
were purchased and allocated to only the first 4 HS participants and the first three oolong
participants. All the participants were instructed to steep 2 g of the teabag in 8 oz. of hot
water, advised to abstain from drinking any other tea aside the one provided, but were not
restricted from their usual dietary and exercise pattern throughout the study period.
Participant’s compliance with tea intake at the end of the study was assessed by asking
them to return unconsumed tea bags, and only readings of those that consumed more than
90% of the tea bags were included in the final data analysis. Finally, volunteers were
informed to report any unusual allergy or abnormal sensations to tea intake and stop
drinking the tea immediately; however, none of the participants reported any adverse
reaction to the tea.
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2.3 Measurements
2.3.1 Blood Pressure
The brachial blood pressure was measured, first in a seated position, and
subsequently in a supine position with an automated sphygmomanometer (Omron HEM907XL, Omron Health Care, Kyoto, Japan). Participants were informed to refrain from
talking while recording the blood pressure readings in both positions. Blood pressure
readings were assessed three times, and average blood pressure readings for both seated
and supine blood were recorded. The blood pressure measurement was standardized by
using the same sphygmomanometer and participant’s right arm throughout the testing
period.
2.3.2 Pulse Wave Analysis
Before performing pulse wave analysis, subjects rested on a bed in the supine
position for 5 minutes. The average supine blood pressure reading obtained was used to
calibrate the SphygmoCor (SphygmoCor CPVH; AtCor Medical, Sydney, Australia).
Radial applanation tonometry was performed non-invasively on each of the participants,
which involved placing a tonometer probe on the radial artery and pressing the probe
slightly against the carpal bone at the wrist. Ten strong radial pulse waves were captured
by pressing/holding the probe for a few seconds on the right spot of the radial artery to
provide trusted estimates of aortic blood pressure. This procedure was done twice to ensure
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consistency in the radial waves and aortic readings generated. An operator index greater
80 was considered satisfactory throughout the testing period.
The radial pulse wave generated was analyzed by the SphygmoCor software to
provide estimates of aortic systolic blood pressure (SAP), diastolic blood pressure (DAP),
mean aortic pressure (MAP) and pulse pressure (PP). Also, aortic augmentation index
(AIx) was calculated automatically by the SphygmoCor software based on the
characteristics of the pulse waves. The procedure was standardized by excluding any
participant with aortic pulse pressure greater than 50 mmHg, as these individuals may be
more susceptible to plaques that could potentially become dislodged with force (Roman et
al., 2007).
2.3.3 Pulse Wave Velocity
The pulse wave velocity was determined by non-invasive applanation tonometry.
Using a three-lead electrocardiogram (ECG) involving the use of three surface electrodes,
two electrodes were placed at the left and right side of the shoulder region, while the last
electrode was placed below the rib cage of the left side of the participants. The distance
(mm) between the pulse site in the carotid artery and the suprasternal notch was measured
with a tape. At the same time, the second distance measured from the femoral pulse located
in the femoral artery and the suprasternal notch was also recorded. Central arterial stiffness
(carotid-femoral) was measured by placing the tonometer on the pulse site first on the
carotid artery and subsequently on the femoral artery on the first trial, while in the opposite
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direction on the second trial. The SphygmoCor software utilizes the measured distance and
the time delay from the appearance of the incident wave in the heart and the arrival of the
reflected wave back at the pulse site for the estimation of carotid-femoral pulse wave
velocity (cfPWV). The test was performed in duplicate to standardize the procedure, and
readings with a standard deviation of ≤ 10% were included in the final data analysis.

2.4 Statistical Analyses
Statistical analysis of the data was performed using IBM SPSS statistics software
(SPSS version 20.0). Analysis of variance (2 x 2 repeated-measures ANOVA) was used
to determine the time and treatment effects on tested variables between the two groups.
Welch two-sample t-test was used to compare the baseline variables due to the unequal
sample size between the two groups. The cfPWV of two participants was not measured,
while one subject did not have recordings for PWA, and was excluded in the final data
analysis. The results were expressed as mean values ± standard deviation (SD), and P-value
< 0.05 was considered significant.
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3 Results
3.1 Participants Characteristics
The baseline demographic and clinical characteristics of the study participants are
shown in Table 3.1. The mean age of the participants in the HS group and control group
was 32 ± 10 years and 27 ± 5, respectively. Generally, there was no significant difference
in the demographic data and tested clinical variables between the two groups at baseline (P
> 0.05).

3.2 Tested Clinical Variables
The within-group and between-group comparisons were analyzed on the following
clinical variables: SBP, DBP, HR, AIx, and cfPWV before and after the intervention. A
reduction in the brachial seated blood pressure was observed within the HS group, with a
decrease in post-intervention mean SBP (-4 mmHg) and DBP (-3 mmHg) when compared
with pre-intervention values. Also, the oolong tea (control) induces reductions in SBP (4mmHg) and DBP (-9.06 mmHg) (Figure 3.1A and B). A 2 x2 repeated-measures ANOVA
between the group revealed a significant time effect for both SBP (P = 0.02) and DBP (P
= 0001). However, there was no significant time by group effect; a reduction in blood
pressure was also observed in the control group.
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Table 3.1. Baseline Demographic and Clinical Characteristics of the Participants
Variable

HS tea

Oolong tea

P-value

n=11

n=7

Age (yrs.)

32 ± 10

27 ± 5

Sex (men/women), n

8/3

5/2

Weight (kg)

82 ± 18

84 ± 16

0.79

Height (cm)

176 ± 10

172 ± 10

0.58

BMI (kg/m2)

26 ± 3

28 ± 4

0.45

Seated SBP (mmHg)

123 ± 7

122 ± 9

0.81

Seated DBP (mmHg)

74 ± 7

70± 9

0.36

Supine SBP (mmHg)

121 ± 7

118 ± 5

0.54

Supine DBP (mmHg)

70 ± 7

64 ± 5

0.06

HR (beats/mins)

64 ± 11

59 ± 10

0.32

AIx@HR75 (%)

3.1 ± 19.0

-0.6 ± 10

0.35

cfPWV (m/s)

6.2 ±0.9

5.5 ± 0.4

0.05

0.17

Values are means ± standard deviation (SD); n: number of participants; HS: Hibiscus
sabdariffa; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood
pressure; HR: Heart rate; AIx@HR75: Aortic augmentation index normalized to 75
heartbeats; cfPWV: Carotid-femoral pulse wave velocity. P-value obtained from Welch
two Sample t-test for baseline comparison between the two groups.
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Figure 3.1. A: comparing mean SBP (systolic blood pressure) pre- vs. 6weeks postintervention; B: mean DBP (diastolic blood pressure) for pre -vs post intervention. A 2 x2
repeated-measures ANOVA between groups revealed significant time effect (P = 0.02; P
= 0.001) for SBP and DBP respectively, and no significant time by group effect (P > 0.05).
Results are mean ± standard deviation (SD).
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Figure 3.2: Comparing the heart rate (HR) before and after intervention between the two
groups. * Significant difference within HS group (P < 0.05). No significant difference
within control (P = 0.69). Repeated ANOVA between the groups revealed a significant
time effect on HR (P =0.028). Results are mean ± standard deviation (SD).
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Figure 3.3: Carotid-femoral pulse wave velocity (cfPWV) before and after intervention
between HS and control groups. Repeated ANOVA revealed no significant time effect (P=
0.44) and time by treatment effect between groups (P =0.35). All values are mean ±
standard deviation (SD)
Also, there was a reduction in HR in both groups when compared with preintervention values (Figure 3.2). However, only the HS tea intervention induced a
significant decrease in HR (P = 0.01) when compared with oolong tea (P= 149), as depicted
in figure 3.2. Furthermore, the carotid-femoral pulse wave velocity (cfPWV) comparison
before and after tea intervention showed a slight reduction in cfPWV (-0.5m/s) in the HS
group, while an increase of (+0.3m/s) was observed in the control group (Figure 3.3).
Although, we did not find any significant time (P= 0.44) and time* treatment group (P=
0.35) effect in both case and the control groups.
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4 Discussion
In this study, we investigated the effects of Hibiscus sabdariffa and Oolong tea on
blood pressure and arterial stiffness in healthy adults. The results showed that the six weeks
tea intervention had a significant positive impact on SBP, DBP, and heart rate. However,
there was no significant time by treatment group effect on the blood pressure, as both SBP
and DBP were also decreased in the Oolong tea group after six weeks of intervention. The
HS tea consumption resulted in a significant decrease in HR, while the observed reduction
in the control group was not statistically significant. To our knowledge, this is the first
study to investigate the effect of HS tea consumption on central arterial stiffness in humans.
There was a slight decrease in the mean cfPWV value within the HS group when compared
with the control, but the reduction was not statistically significant.
The partial oxidation and fermentation of Camellia sinensis plant leaves results in the
production of Oolong tea. The concentration of caffeine in the tea derived from Camellia
sinensis depends on the method of cultivation and intensity of oxidation during processing.
While the caffeine content in oolong tea is considerably small when compared to black tea,
although excessive consumption could also stimulate an acute rise in blood pressure.
Several clinical trials on the antihypertensive effect of oolong tea and other tea derived
from Camellia sinensis (green and black tea) reported convincing data that need to be
verified and confirmed. In this current study, both the HS and Oolong tea (control) lowered
blood pressure. The results from this study are in agreement with most of the previous
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clinical and experimental studies on antihypertensive effects of HS tea. In a clinical trial,
where the impact of HS tea on stage 1 hypertensive patients was investigated, a decrease
in blood pressure was reported in both the case and the control groups (Jalalyazdi et al.,
2019). In another trial, the effect of HS tea consumption on patients with mild hypertension
resulted in significant reductions in SBP, DBP, and MAP when consumed thrice daily for
six weeks (McKay et al., 2009). A meta-analysis of 13 RCTs on the effect of green tea
consumption on blood pressure showed a significant decrease in SBP and DBP by 1.98
mmHg and 1.92 mmHg, respectively, when compared to the control group (Peng et al.,
2014).
Contrary to our study, is a RCT that compared the antihypertensive effect of HS tea
with green tea in healthy adult men. The study concluded that the daily administration of
450mg of HS could induce a significant reduction in only SBP when compared with green
tea, the study did not report any significant difference in DBP in either the HS and green
tea intervention (Kafeshani et al., 2017). While, another meta-analysis of 5 RCTs showed
no significant changes in the blood pressure after about four weeks of oolong tea
consumption (Liu et al., 2014).
The significant decrease in HR within the participants exposed to HS tea when
compared to control in this study is similar to the reports obtained from another randomized
clinical trial. In the previous study, a significant reduction in HR was observed after the
administration of 15mg/kg of HS extract to individuals with increased HR-induced by
hand-grip exercise (HE) and cold pressor test (Aliyu et al., 2014). Also, reports from an
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animal study confirmed the HR reduction induced by HS extract. Chronic ingestion of HS
extract (250mg/kg/day) into renovascular hypertensive-induced rats for eight weeks
resulted in a significant decrease in HR (Odigie, Ettarh, & Adigun, 2003). The probable
mechanism of reducing HR has been associated with HS’s ability to inhibit sympathetic
nerve activity. It was reported that the activation of SNS induced by CPT, which led to the
stimulation of pain, cold receptors, constriction of blood vessels, caused an increase in HR.
The subsequent administration of HS extract counteracted the activated SN activity,
thereby mediating the reduction in HR back to normal (Aliyu et al., 2014).
Despite the numerous cardioprotective effects of HS reported in previous studies, the
specific antihypertensive mechanisms of HS are not fully understood. Different
antihypertensive mechanisms have been reported; regulating serum electrolyte due to its
diuretic effect (Herrera-Arellano et al., 2007), ACE inhibitory activity (Ojeda et al., 2010),
inhibition of SNS and regulation of blood lipids (Morales‐Luna et al., 2019), which are all
involved in the pathogenesis of hypertension Recently, the anthocyanin which is the
bioactive compound in HS extract has been reportedly linked to most of the
antihypertensive mechanisms of HS. This was confirmed in an animal study where the
effect of dried HS calyx was compared with HS anthocyanin (HSA) extract on spontaneous
hypertensive rats. It was indicated that long-term ingestion (10 weeks) of HSA resulted in
a significant reduction in SBP, DBP, and left ventricular mass when compared to the whole
HS calyx (Inuwa et al., 2012). Similarly, the probable antihypertensive mechanism of
oolong tea can be linked to the concentration of “catechins,” which is the bioactive
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compound in tea. Catechins have been shown to induce the release of NO from the
endothelium, which can inhibit the constriction of blood vessels. Extracts from Camellia
sinensis lowers blood pressure by enhancing the production of antioxidant enzymes that
inactivate reactive oxygen species (ROS). The antioxidant enzymes includes; catalase,
glutathione peroxidase, glutathione reductase and superoxide dismutase (Thomson, AlQattan, Mansour, & Ali, 2012)
As previously stated, arterial stiffness is one of the most common mechanisms that
could contribute to the development of hypertension, increased arterial stiffness has been
associated with aging, high blood pressure and increased risk of cardiovascular diseases.
In this study, we investigated the effect of HS tea on arterial stiffness as a probable
mechanism by which HS tea could decrease blood pressure. While the observed slight
decrease in cfPWV (-0.5m/s) was not statistically significant with our limited sample-size,
the -0.5m/s reduction could be clinically significant as 1m/s reduction in cfPWV could all
reduce CVD-induced mortality by 15% (Vlachopoulos, Aznaouridis, & Stefanadis, 2010).
Thus, the 0.5 m/s reduction after HS could indicate the risk for mortality is reduced by
approximately 7.5%.

4.1 Limitations
Generally, the variability in response reported in this study and some previous HS
clinical trials have been linked to lack of standardization in the amount of HS consumed,
different methods/conditions used in the preparation of HS (infusion, extraction or
decoctions) and the methods of use by the trial participants (a varying amount of water and
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temperature condition). All those factors listed above would affect the dose of the bioactive
compound (anthocyanins) in HS given to trial participants.
One major limitation of this study was our small size. The sample size was
considerably small due to participants who were lost to follow-up because of the COVID19 pandemic. The imbalance in the number of participants between the HS and the control
groups was a concern, as more of the participants lost to follow-up were in the control
group. Also, the true blinding of our treatments was not feasible because of the distinct
tastes of HS and the oolong tea used as control. Furthermore, in this trial, we used dried
calyx of HS, measured, and packed in the teabags, we were unable to extract and
standardize the amount of the active anthocyanins in the HS tea consumed by the
participants, and thus could lead to some variability in the doses of bioactive compound.
Lastly, most of the participants recruited for this study were volunteers studying at the
university, so we were unable to completely exclude other confounding factors such as
stress, diets, and exercise conditions that could potentially influence the cardiovascular
measurements.

4.2 Future Directions
Future studies on the antihypertensive effects of HS on humans should be well
standardized by extracting the anthocyanin bioactive compound from the dried calyx. The
quantification of anthocyanin doses by high-performance liquid chromatography coupled
with mass spectrometry (HPLC-MS) before administering it to trial participants is highly
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recommended to achieve the desired hypotensive effects and at the same time preventing
HS overdose that could potentially be toxic to some organs in the body. Previous studies
on the HPLC analysis of HS have shown the presence of four different types of
anthocyanins in HS extract; however, a large amount of delphinidin-3-O- sambubioside
(Dp-samb) has been reported. As such, we recommend further fractionation of HS to
separate the Dp-samb from other anthocyanins in the HS extract before consumption to
achieve maximum benefits. Also, more robust, randomized controlled clinical trials with
a high dosage of Dp-samb targeted for a longer duration of intervention would be desirable
to achieve the beneficial effects of HS extract in the treatment of hypertension.
The selection of the most desirable control tea that would not have any effect on the
cardiovascular system was a challenge to our study and most of the previous RCTs. While
trying to select a tea that would have the same color and similar sour taste like HS tea to
ensure blinding of the participants, it is also imperative to choose a tea that lacks the
bioactive anthocyanin compounds found in HS tea. We conducted a small preliminary
study, by randomizing four participants to a peach control tea, which has a light red color
and somewhat sour taste. It was observed that all the tested cardiovascular variables remain
unchanged after six weeks of peach tea consumption (Figure 3.4 A-D).
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Figure 3.4 A: Comparing systolic blood pressure (SBP), B: Diastolic blood pressure
(DBP), C: Aortic augmentation index (AIX), and D: Carotid-femoral pulse wave velocity
(cfPWV) before and after peach tea consumption. Results are mean ±SD.
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In figure 3.4 above, there were no changes in all the measured cardiovascular
variables after six weeks of drinking peach tea when compared to baseline measurements.
Based on these promising preliminary findings, we recommend the use of peach tea as a
reliable control in future tea studies. RCTs with an active control protocol would be
superior to many of the previous studies on tea that have used a wait-list period in place of
randomization into an active control group.
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A. Appendix A- Raw Data
A.1

Participant’s Baseline Characteristics

Table A.1: Baseline Demographics and Clinical Characteristics Raw Data
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A.2

Blood Pressure Measurements
Table A.2. Pre and Post Intervention Blood Pressure Readings Raw Data

Participant

Pre- SBP
(seated)

Pre- DBP
(seated)

Post- SBP
(seated)

Post- DBP
(seated)

Pre - PP

Post- PP

1

124

68

125

66

56

59

2

110

70

121

67

40

54

3

130

89

121

79

41

42

4

130

80

116

79

51

37

5

127

69

124

68

58

60

6

123

81

120

71

42

49

7

130

75

128

77

55

51

8

126

70

120

70

56

50

9

118

71

112

71

47

41

10

126

66

128

71

60

57

11

114

71

99

62

43

37

12

110

68

116

66

42

50

13

118

73

111

69

45

42

14

137

75

127

67

62

60

15

129

80

126

77

49

49

16

114

74

111

69

40

42

17

122

66

117

58

56

59

18

127

53

120

46

74

74

66

19

114

68

N/A

N/A

46

N/A

20

127

77

N/A

N/A

50

N/A

21

118

80

N/A

N/A

38

N/A

22

123

71

N/A

N/A

52

N/A

23

112

58

N/A

N/A

54

N/A

24

129

86

N/A

N/A

43

N/A

25

114

73

N/A

N/A

41

N/A

26

111

66

N/A

N/A

45

N/A

27

124

73

N/A

N/A

51

N/A

28

117

70

N/A

N/A

47

N/A

29

124

75

N/A

N/A

49

N/A

30

122

71

N/A

N/A

51

N/A

SBP- Systolic blood pressure (mmHg); DBP- Diastolic blood pressure (mmHg); PPPulse pressure; N/A -missing values due to lack of follow-up.
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A.3 Central Hemodynamics Measurements
Table A.3. Pre- and Post-intervention Central Hemodynamics Measurements Raw Data
Participant PreSAP

PreDAP

PostSAP

PostDAP

PrePostAIX@ AIX@
HR75 HR75

1

91

64

101

64

2.5

8

5.1

5.2

2

97

65

97

66

11.5

11

5.9

4.6

3

121

88

113

79

23

25

N/A

N/A

4

119

78

114

84

38

31

6.2

6.2

5

105

63

103

65

-13

-10

4.8

6.2

6

N/A

N/A

N/A

N/A

N/A

NA

7.9

6.1

7

104

71

106

67

5.5

6

7.2

6.8

8

102

71

99

71

-

23

5.7

6.6

9

107

72

100

71

13

2

6.2

5.6

10

104

66

104

72

-22

-10

6.5

5.3

11

97

53

86

63

-14

-15

6.2

5.3

12

97

69

91

56

11.5

7

5.2

4.9

13

102

74

88

64

1..0

2

4.8

4.8

14

101

64

110

170

2

5

5.2

5.4

15

95

69

94

66

3.5

0

N/A

NA

16

99

68

100

67

6

9.5

6.1

5.6

17

99

66

92

58

-17

-30

5.6

6.1

18

97

53

95

47

-11

-1

5.8

6.1

19

101

67

NA

NA

NA

NA

NA

NA

68

PrePostcfPWV cfPWV

20

106

69

NA

NA

NA

NA

NA

NA

21

104

76

NA

NA

NA

NA

NA

NA

22

94

65

NA

NA

NA

NA

NA

NA

23

81

49

NA

NA

NA

NA

NA

NA

24

103

77

NA

NA

NA

NA

NA

NA

25

96

63

NA

NA

NA

NA

NA

NA

26

88

57

NA

NA

NA

NA

NA

NA

27

87

59

NA

NA

NA

NA

NA

NA

28

94

55

NA

NA

NA

NA

NA

NA

29

102

78

NA

NA

NA

NA

NA

NA

30

99

61

NA

NA

NA

NA

NA

NA

SAP -Systolic aortic pressure; DAP- Diastolic aortic pressure; AIX@HR75- Aortic
augmentation index in 75beats; cfPWV- Carotid-femoral pulse wave velocity; N/A missing values due to absence of follow up
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A.4. Peach tea Control Raw Data for the Pilot study
Table A.4. Baseline and Post Peach Tea Intervention Raw Data

Participant

PrePrePostPostSBP
DBP
SBP
DBP
(supine) (supine) (supine) (supine)

PreAIX

PostAIX

PrePostcfPWV cfPWV

1

117

66

114

69

13

20

5

5

2

118

68

119

69

24

17

6.6

6.6

3

122

74

127

72

2.5

12.5

5.9

6.2

4

113

65

116

70

8

7

7.1

6.9

SBP-Systolic blood pressure; DBP-Diastolic blood pressure; Aix- Aortic
augmentation index, cfPWV- Carotid-femoral pulse wave velocity.
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B

APPENDIX B- Statistical Analyses

Table B.1 a Descriptive Statistics Of SBP

Mean

Std.
Deviation

N

123.4545

6.74335

11

Camellia_sinensis

122.4286

9.32483

7

Total

123.0556

7.59622

18

119.4545

8.29896

11

Camellia_sinensis

118.2857

6.47339

7

Total

119.0000

7.45970

18

Treatment
Pre_SBP

Hibiscus

Post_SBP

Hibiscus

Table B.1b- Multivariate Tests by 2x2 Repeated-measures ANOVA

Effect
time

Value

F

Hypothesis df Error df

Sig.

Pillai's Trace

.288

6.457b

1.000

16.000

.022

Wilks' Lambda

.712

6.457b

1.000

16.000

.022

Hotelling's Trace

.404

6.457b

1.000

16.000

.022

Roy's Largest Root

.404

6.457b

1.000

16.000

.022

time * Treatment
Pillai's Trace

.000

.002b

1.000

16.000

.965

Wilks' Lambda

1.000

.002b

1.000

16.000

.965
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Hotelling's Trace

.000

.002b

1.000

16.000

.965

Table B.1c – Tests of Within-Subjects Effects

Measure: MEASURE_1
Type III Sum
of Squares

Source

Df

Mean Square F

141.821

1

141.821

6.457

Greenhouse-Geisser

141.821

1.000

141.821

6.457

Huynh-Feldt

141.821

1.000

141.821

6.457

Lower-bound

141.821

1.000

141.821

6.457

.044

1

.044

.002

Greenhouse-Geisser

.044

1.000

.044

.002

Huynh-Feldt

.044

1.000

.044

.002

Lower-bound

.044

1.000

.044

.002

351.429

16

21.964

Greenhouse-Geisser

351.429

16.000

21.964

Huynh-Feldt

351.429

16.000

21.964

Lower-bound

351.429

16.000

21.964

time

Sphericity Assumed

time * Treatment
Assumed

Error(time)

Sphericity

Sphericity Assumed

73

Table B.1d: Test of Between- Subjects Effect

Source

Type III Sum
of Squares

df

Mean Square F

1

500268.081 5114.010 .000

.997

Treatment 10.303

1

10.303

.007

Error

16

97.823

Intercept

500268.081

1565.169

Sig.

Partial Eta
Squared

.105

.750

Table B.2: Descriptive Statistics of DBP

Treatment
Pre_DBP

Mean

N

73.6364 6.96093

11

Camellia_sinensis

69.8571 8.74507

7

Total

72.1667 7.68689

18

71.0000 5.44059

11

Camellia_sinensis

64.5714 9.91392

7

Total

68.5000 7.90569

18

Post_DBP

Hibiscus

Std.
Deviation

Hibiscus
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Table B.2a: ANOVA for DBP

Effect

Value

F

.486

15.126b

1.000

16.000

.001

Wilks' Lambda

.514

15.126b

1.000

16.000

.001

Hotelling's Trace

.945

15.126b

1.000

16.000

.001

Roy's Largest Root

.945

15.126b

1.000

16.000

.001

.096

1.692b

1.000

16.000

.212

Wilks' Lambda

.904

1.692b

1.000

16.000

.212

Hotelling's Trace

.106

1.692b

1.000

16.000

.212

Roy's Largest Root

.106

1.692b

1.000

16.000

.212

time

Pillai's Trace

time * Treatment

Pillai's Trace

Hypothesis Error df
df

Sig.

Table B.2b: Tests of Between-Subjects Effects

Source

Type III Sum
of Squares

df

Mean Square

166570.759 1579.684

Intercept

166570.759

1

Treatment

222.870

1

222.870

Error

1687.130

16

105.446

75

F

2.114

Sig.

Partial Eta
Squared

.000

.990

.165

.117

Table B.3a- Descriptive Statistics for HR

64.2727

Std.
Deviation
10.84519

11

Camellia_sinensis

59.1429

9.90671

7

Total

62.2778

10.50941

18

58.0000

9.02219

11

Camellia_sinensis

57.7143

11.77164

7

Total

57.8889

9.83923

18

Treatment
Pre_HR

Mean

Hibiscus

Post_HR

Hibiscus

N

Table B.3b -ANOVA test for HR
Partial Eta
Squared

Effect
time

Pillai's Trace

Noncent.
Parameter

Observed
Powerc

.266

5.800

.619

Wilks' Lambda

.266

5.800

.619

Hotelling's Trace

.266

5.800

.619

.266

5.800

.619

Pillai's Trace .125

2.295

.297

Roy's Largest Root
time * Treatment

Wilks' Lambda

.125

2.295

.297

Hotelling's Trace

.125

2.295

.297

.125

2.295

.297

Roy's Largest Root
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Table B.3c -Tests of Between Subjects Effect

Partial Eta
Squared

Noncent.
Parameter

Observed
Powerc

.266

5.800

.619

Wilks' Lambda

.266

5.800

.619

Hotelling's Trace

.266

5.800

.619

Roy's Largest Root

.266

5.800

.619

.125

2.295

.297

Wilks' Lambda

.125

2.295

.297

Hotelling's Trace

.125

2.295

.297

Roy's Largest Root

.125

2.295

.297

Effect
time

Pillai's Trace

time * Treatment

Pillai's Trace

Table B.3d -Tests of Within-Subjects Effect

Source

Type III Sum
of Squares

df

Mean Square

F

126.858

1

126.858

5.800

Greenhouse-Geisser

126.858

1.000

126.858

5.800

Huynh-Feldt

126.858

1.000

126.858

5.800

Lower-bound

126.858

1.000

126.858

5.800

time * Treatment
Sphericity
Assumed

50.191

1

50.191

2.295

Greenhouse-Geisser

50.191

1.000

50.191

2.295

time

Sphericity Assumed
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Huynh-Feldt

50.191

1.000

50.191

2.295

Lower-bound

50.191

1.000

50.191

2.295

349.948

16

21.872

Greenhouse-Geisser

349.948

16.000

21.872

Huynh-Feldt

349.948

16.000

21.872

Lower-bound

349.948

16.000

21.872

Error(time)

Sphericity Assumed

Table B.4a -Descriptive Statistics for Carotid-femoral Pulse wave velocity (cfPWV)
Treatment

Mean

Std.
Deviation

N

6.1700

.91171

10

Camellia_sinensis

5.4500

.47223

6

Total

5.9000

.83825

16

Post_cfPWV Hibiscus

5.7900

.69833

10

Camellia_sinensis

5.4833

.56362

6

Total

5.6750

.64962

16

Pre_cfPWV

Hibiscus
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Table B.4a – ANOVA Test for cfPWV
Two by two -repeated measures ANOVA
for testing the time effect and time b y treatment group
effect for the carotid-femoral pulse wave velocity

Effect
time

Value

F

.044

.647b

1.000

14.000

.435

Wilks' Lambda

.956

.647b

1.000

14.000

.435

Hotelling's Trace

.046

.647b

1.000

14.000

.435

Roy's Largest Root

.046

.647b

1.000

14.000

.435

.062

.920b

1.000

14.000

.354

Wilks' Lambda

.938

.920b

1.000

14.000

.354

Hotelling's Trace

.066

.920b

1.000

14.000

.354

Roy's Largest Root

.066

.920b

1.000

14.000

.354

Pillai's Trace

time * Treatment

Pillai's Trace

Hypothesis df Error
df

Sig.

Table B.4b – Tests of Within-Subjects Effects

Source
time

Type III Sum
of Squares

df

Mean Square

F

.225

1

.225

.647

Greenhouse-Geisser

.225

1.000

.225

.647

Huynh-Feldt

.225

1.000

.225

.647

Sphericity Assumed
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Lower-bound

.225

1.000

.225

.647

time * Treatment
Sphericity
Assumed

.320

1

.320

.920

Greenhouse-Geisser

.320

1.000

.320

.920

Huynh-Feldt

.320

1.000

.320

.920

Lower-bound

.320

1.000

.320

.920

4.875

14

.348

Greenhouse-Geisser

4.875

14.000

.348

Huynh-Feldt

4.875

14.000

.348

Lower-bound

4.875

14.000

.348

df

Mean Square

F

Sig.

.225

1

.225

.647

.435

.320

1

.320

.920

.354

4.875

14

.348

Error(time)

Sphericity Assumed

Table B.5c – Tests of Within-Subjects Contrast

Source time
time

Linear

time * Treatment
Linear
Error(time)

Linear

Type III Sum
of Squares
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Table B.5d – Tests of Between-Subjects Effects
Table showing the time effect and time by treatment group effect between the subjects

Source time
time

Linear

time * Treatment
Linear
Error(time)

Linear

Type III Sum
of Squares

df

Mean Square

F

Sig.

.225

1

.225

.647

.435

.320

1

.320

.920

.354

4.875

14

.348
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